Are fish oil supplements for CV protection dead in the water?

  • Abbasi J
  • JAMA
  • 18 Apr 2018

  • curated by Emily Willingham, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Conflicting findings have left an aftertaste of doubt about the usefulness of fish oil supplements  against cardiovascular disease (CVD).
  • A 2018 meta-analysis of 10 clinical trials found little benefit, contrasting somewhat with an American Heart Association (AHA) science advisory that supplements could be considered for patients with recent myocardial infarction.
  • 4 in-progress trials may help decide whether fish oil supplements can sink or swim.
  • In the meantime, the risk of using the supplements appears to be minimal. 

Why this matters

  • Fish oil supplements had shown promise in reducing CVD-related endpoints, but mounting evidence casts doubt on that potential.

Key results

  • The 2018 meta-analysis included 10 trials with 77,917 participants; the authors concluded that supplements offer no benefit. 
  • The AHA advisory concluded that without high CVD risk, the supplements offer no benefit, but called supplementation “reasonable” as secondary prevention postmyocardial infarction.
  • 4 upcoming trials to watch:
    • ASCEND (A Study of Cardiovascular Events iN Diabetes, Phase 4): 100 mg aspirin vs placebo or omega-3 fatty acids (omega-3s) in patients with diabetes; endpoint, serious vascular event prevention; estimated completion date was September 2017.
    • VITAL (VITamin D and OmegA-3 TriaL, Phase 3): randomized trial with 25,871 participants taking daily vitamin D or omega-3s; endpoints are cancer, heart disease, stroke risk; estimated completion date, June 2018.
    • REDUCE-IT (Phase 3): this population has hypertriglyceridemia, and the test drug is a purified omega-3; endpoint, long-term cardiovascular event reduction; estimated complete date, July 2018.
    • STRENGTH (Phase 3): omega-3s in patients with high CVD risk and hypertriglyceridemia; endpoint, major adverse cardiac events; estimated completion date, October 2019.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit